Skip to main content
SpringerLink
Log in

Overview of the Pharmacology of the Aromatase Inactivator Exemestane

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

One third of all breast cancers and two thirds of postmenopausal breast cancers are estrogen dependent. Antiestrogen strategies, such as inhibition of estrogen-receptor binding and estrogen deprivation, are effective for the management of hormone-dependent breast cancer. Although currently available agents are effective, the development of more potent and selective agents continues. Both steroidal and nonsteroidal inhibitors of aromatase have been developed for clinical uses. A novel class of steroidal irreversible antiaromatase agents demonstrates a high degree of specificity for the aromatase enzyme and exhibits a unique pharmacokinetic profile. The ability of these agents to inactivate aromatase may explain their high degree of potency and lengthy duration of action. Exemestane, an orally active aromatase inactivator, has demonstrated excellent selectivity and tolerability and broad-based efficacy in the treatment of postmenopausal breast cancer. Current findings suggest that exemestane will be a valuable alternative for women with breast cancer, not only for those progressing on other hormonal therapies but in earlier stages of the disease and prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lippman ME, Dickson RB: Growth control of normal and ma-lignant breast epithelium. Prog Clin Biol Res 354: 147–178, 1990

    Google Scholar 

  2. Carmichael PL: Mechanisms of action of antiestrogens: relev-ance to clinical benefits and risks. Cancer Invest 16: 604–611, 1998

    PubMed  Google Scholar 

  3. Cole PA, Robinson CH: Mechanism and inhibition of cyto-chrome P-450 aromatase. J Med Chem 33: 2933–2942, 1990

    PubMed  Google Scholar 

  4. Brueggemeier RW: Biochemical and molecular aspects of aromatase. J Enzyme Inhibit 4: 101–110, 1990

    Google Scholar 

  5. Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ: The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100: 1684–1695, 1977

    PubMed  Google Scholar 

  6. Dowsett M: Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol 5: S3–5, 1994

    Google Scholar 

  7. Dowsett M: Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res Treat 49: S39–44, 1998; discus-sion S73-37

    PubMed  Google Scholar 

  8. Bajetta E, Celio L, Buzzoni R, Bichisao E: Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Tumori 82: 417–422, 1996

    PubMed  Google Scholar 

  9. Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN: Effect of estrogen deprivation on the repro-ductive physiology of male and female primates. J Steroid Biochem Mol Biol 61: 157–166, 1997

    PubMed  Google Scholar 

  10. Di Salle E, Briatico G, Giudici D, Ornati G, Zaccheo T, Buzzetti F, Nesi M, Panzeri A: Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol 49: 289–294, 1994

    PubMed  Google Scholar 

  11. Brueggemeier RW: Aromatase inhibitors-mechanisms of steroidal inhibitors. Breast Cancer Res Treat 30: 31–42, 1994

    PubMed  Google Scholar 

  12. Goss PE, Jarman M, Wilkinson JR, Coombes RC: Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J Steroid Biochem 24: 619–622, 1986

    Google Scholar 

  13. Wiseman LR, Goa KL: Formestane. A review of its pharma-cological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 9: 292–306, 1996

    PubMed  Google Scholar 

  14. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E: 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 30: 391–394, 1988

    PubMed  Google Scholar 

  15. Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, Coombes RC: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52: 5933–5939, 1992

    PubMed  Google Scholar 

  16. Lonning PE: Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 49: S45–52, 1998

    PubMed  Google Scholar 

  17. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089–2093, 1998.

    PubMed  Google Scholar 

  18. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozole (Ar-imidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmeno-pausal women with breast cancer. Br J Cancer 74: 1286–1291, 1996

    PubMed  Google Scholar 

  19. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511–1515, 1995

    PubMed  Google Scholar 

  20. Di Salle E, Giudici D, Briatico G, Ornati G: Novel irreversible aromatase inhibitors. Ann N Y Acad Sci 595: 357–367, 1990

    PubMed  Google Scholar 

  21. Buzzetti F, Di Salle E, Longo A, Briatico G: Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). Steroids 58: 527–532, 1993

    PubMed  Google Scholar 

  22. Di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC: Exemestane (FCE 24304), a new steroidal aro-matase inhibitor. J Steroid Biochem Mol Biol 43: 137–143, 1992

    PubMed  Google Scholar 

  23. Bajetta E, Zilembo N, Noberasco C, Martinetti A, Mariani L, Ferrari L, Buzzoni R, Greco M, Bartoli C, Spagnoli I, Danesini GM, Artale S, Paolini J: The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 33: 587–591, 1997

    PubMed  Google Scholar 

  24. Lonning PE: Aromatase inhibition for breast cancer treatment. Acta Oncol 35: 38–43, 1996

    PubMed  Google Scholar 

  25. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089–2093, 1998

    PubMed  Google Scholar 

  26. Miller WR: Biology of aromatase inhibitors: pharmaco-logy/ endocrinology within the breast. Endocr Relat Cancer 6: 187–195, 1999

    PubMed  Google Scholar 

  27. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE:Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3: 1101–1108, 1997

    PubMed  Google Scholar 

  28. Di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG: Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta MS, M (ed), Sex Hormones and Antihormones in Endocrine De-pendent Pathology: Basic and Clinical Aspects.Elsevier, Amsterdam, 1994, pp. 303–310

    Google Scholar 

  29. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffran-chi A, Di Salle E: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72: 1007–1012, 1995

    PubMed  Google Scholar 

  30. Dowsett M Coombes RC: Second generation aromatase in-hibitor-4-hydroxyandrostenedione. Breast Cancer Res Treat 30: 81–87, 1994

    PubMed  Google Scholar 

  31. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acet-ate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399–1411, 2000

    PubMed  Google Scholar 

  32. Johnston JO, Wright CL, Metcalf BW: Time-dependent inhib-ition of aromatase in trophoblastic tumor cells in tissue culture. J Steroid Biochem 20: 1221–1226, 1984

    PubMed  Google Scholar 

  33. Brueggemeier RW, Katlic NE: Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures. Cancer Res 50: 3652–3656, 1990

    PubMed  Google Scholar 

  34. Yue W, Brodie AM: Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and amino-glutethimide on aromatase in JEG-3 cell culture. J Steroid Biochem Mol Biol 63: 317–328, 1997

    PubMed  Google Scholar 

  35. Harada N, Honda SI, Hatano O: Aromatase inhibitors and enzyme stability. Endocr Relat Cancer 6: 211–218, 1999

    PubMed  Google Scholar 

  36. Chen S, Zhou D, Okubo T, Kao YC, Yang C: Breast tumor aro-matase: functional role and transcriptional regulation. Endocr Relat Cancer 6: 149–156, 1999

    PubMed  Google Scholar 

  37. Soudon J: Comparison of in vitro exemestane activity versus other antiaromatase agents. Clin Breast Cancer 1: S68-S73, 2000

    PubMed  Google Scholar 

  38. Miller WR, Dixon JM: Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 1: S9-S14, 2000

    PubMed  Google Scholar 

  39. Longcope C: Methods and results of aromatization studies in vivo. Cancer Res 42: 3307s-3311s, 1982

    PubMed  Google Scholar 

  40. Schweikert HU, Milewich L, Wilson JD: Aromatization of androstenedione by cultured human fibroblasts. J Clin Endo-crinol Metab 43: 785–795, 1976

    Google Scholar 

  41. Perel E, Killinger DW: The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem 10: 623–627, 1979

    PubMed  Google Scholar 

  42. Miller WR, Forrest AP: Oestradiol synthesis from C19 ster-oids by human breast cancers. Br J Cancer 33: 116–118, 1976

    PubMed  Google Scholar 

  43. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH: Endogenous concentration and subcellular distribution of es-trogens in normal and malignant human breast tissue. Cancer Res 45: 2900–2906, 1985

    PubMed  Google Scholar 

  44. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, Di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, phase II trial of ex-emestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17: 3418–3425, 1999

    PubMed  Google Scholar 

  45. Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G: Third-line hormonal treatment with exemestane in post-menopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 33: 1767–1773, 1997

    Google Scholar 

  46. Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G: Activity of exemestane in metastatic breast can-cer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18: 2234–2244, 2000

    PubMed  Google Scholar 

  47. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Lobelle JP, Piccart M: Activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (PT) (abstract). Breast Cancer Res Treat 64: 52a, 2000

    Google Scholar 

  48. Dirix L, Piccart MJ, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Duchateau L, Lobelle JP, Paridaens R: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment on Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 21: 2001.

  49. Tedeschi M, Kvinnsland S, Jones SE, Kaufmann M, Polli A, Fowst C, Massimini G: Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin (exemestane), in advanced breast cancer patients having progressed on antiestrogens (abstract). Presented at ECCO 1999

  50. Goss PE, Strasser K: Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer. J Clin Oncol 19: 881–894, 2001

    PubMed  Google Scholar 

  51. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ: Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73: 543–548, 1996

    PubMed  Google Scholar 

  52. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M: Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77: 324–331, 1993

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, The Ohio State University, 642 Riffe Building, Columbus, OH, USA

    Robert W. Brueggemeier

Authors
  1. Robert W. Brueggemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brueggemeier, R.W. Overview of the Pharmacology of the Aromatase Inactivator Exemestane. Breast Cancer Res Treat 74, 177–185 (2002). https://doi.org/10.1023/A:1016121822916

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016121822916

Search

Navigation